Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Provided By Globe Newswire
Last update: Aug 10, 2022
- Oral fadraciclib demonstrated good tolerability with continuous dosing;
anticipate entering Phase 2 POC stage in 2H 2022 –
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (7/11/2025, 8:02:39 PM)
After market: 4.12 -0.79 (-16.09%)4.91
-0.05 (-1.01%)
3.71
-0.49 (-11.67%)
Find more stocks in the Stock Screener
